A randomized-controlled, clinical trial with repeated doses of AstroRx for Amyotrophic lateral sclerosis
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Astrocyte cell therapy Kadimastem (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- 18 Jul 2024 According to Pluri media release, Pluris CDMO selected to manufacture Astrocyte-cell-therapy-Kadimastem for this trial
- 09 Aug 2022 According to a Kadimastem media release, the company is currently engaged in intensive activities to submit the IND by the end of 2022 as well as preparations for the start this Phase IIa clinical study in 2023 in the United States.
- 22 Dec 2020 New trial record